---
document_datetime: 2025-04-29 11:28:59
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/xenleta-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: xenleta-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.0147774
conversion_datetime: 2025-12-27 19:46:41.607466
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Xenleta

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                   | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                                                                                                                                               |
|----------------------|-----------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0010               | Renewal of the marketing authorisation. | 30/01/2025                          | 04/04/2025                                  | SmPC, Annex II, Labelling and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Xenleta in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| PSUSA/10872 /202408   | Periodic Safety Update EU Single assessment - lefamulin                                                                                                   | 13/03/2025   | n/a        |      | PRAC Recommendation - maintenance                                                                                            |
|-----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------|------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10872 /202308   | Periodic Safety Update EU Single assessment - lefamulin                                                                                                   | 07/03/2024   | n/a        |      | PRAC Recommendation - maintenance                                                                                            |
| PSUSA/10872 /202208   | Periodic Safety Update EU Single assessment - lefamulin                                                                                                   | 16/03/2023   | n/a        |      | PRAC Recommendation - maintenance                                                                                            |
| PSUSA/10872 /202202   | Periodic Safety Update EU Single assessment - lefamulin                                                                                                   | 29/09/2022   | n/a        |      | PRAC Recommendation - maintenance                                                                                            |
| PSUSA/10872 /202108   | Periodic Safety Update EU Single assessment - lefamulin                                                                                                   | 10/03/2022   | n/a        |      | PRAC Recommendation - maintenance                                                                                            |
| PSUSA/10872 /202102   | Periodic Safety Update EU Single assessment - lefamulin                                                                                                   | 30/09/2021   | n/a        |      | PRAC Recommendation - maintenance                                                                                            |
| IB/0005               | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                 | 23/06/2021   | 08/07/2022 | SmPC | To change the shelf life of the finished product form 3 to 4 years in section 6.3 of the Summary of Product Characteristics. |
| PSUSA/10872 /202008   | Periodic Safety Update EU Single assessment - lefamulin                                                                                                   | 11/03/2021   | n/a        |      | PRAC Recommendation - maintenance                                                                                            |
| IB/0003               | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                            | 22/02/2021   | n/a        |      |                                                                                                                              |
| IA/0001/G             | This was an application for a group of variations. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process | 28/10/2020   | n/a        |      |                                                                                                                              |

<div style=\"page-break-after: always\"></div>

| of the AS B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|